Capital International Inc. CA Acquires 22,523 Shares of Qiagen N.V. $QGEN

Capital International Inc. CA raised its holdings in shares of Qiagen N.V. (NYSE:QGEN) by 4.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 506,461 shares of the company’s stock after buying an additional 22,523 shares during the quarter. Capital International Inc. CA owned about 0.23% of Qiagen worth $22,629,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Smartleaf Asset Management LLC grew its stake in shares of Qiagen by 1,383.3% in the third quarter. Smartleaf Asset Management LLC now owns 890 shares of the company’s stock worth $39,000 after acquiring an additional 830 shares during the last quarter. MAI Capital Management raised its stake in Qiagen by 998.9% during the 2nd quarter. MAI Capital Management now owns 978 shares of the company’s stock valued at $47,000 after purchasing an additional 889 shares during the last quarter. Allworth Financial LP boosted its holdings in Qiagen by 260.1% in the 2nd quarter. Allworth Financial LP now owns 1,102 shares of the company’s stock valued at $53,000 after purchasing an additional 796 shares during the period. GAMMA Investing LLC boosted its holdings in Qiagen by 375.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,241 shares of the company’s stock valued at $55,000 after purchasing an additional 980 shares during the period. Finally, Jones Financial Companies Lllp grew its position in Qiagen by 64.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,610 shares of the company’s stock worth $71,000 after purchasing an additional 628 shares during the last quarter. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Trading Down 0.8%

Shares of Qiagen stock opened at $43.01 on Wednesday. Qiagen N.V. has a 52-week low of $40.14 and a 52-week high of $57.81. The firm has a market capitalization of $9.08 billion, a PE ratio of 21.33, a price-to-earnings-growth ratio of 2.11 and a beta of 0.70. The company has a debt-to-equity ratio of 0.44, a current ratio of 3.90 and a quick ratio of 3.31. The company’s fifty day moving average price is $49.70 and its two-hundred day moving average price is $49.05.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Thursday, February 5th. The company reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.61 by $0.01. Qiagen had a net margin of 20.33% and a return on equity of 14.56%. The company had revenue of $540.42 million during the quarter, compared to the consensus estimate of $528.53 million. During the same period last year, the firm earned $0.61 EPS. The firm’s revenue for the quarter was up 3.6% compared to the same quarter last year. On average, analysts expect that Qiagen N.V. will post 2.26 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Citigroup dropped their price objective on shares of Qiagen from $55.40 to $55.00 and set a “neutral” rating on the stock in a report on Friday, February 6th. Stifel Nicolaus set a $50.00 target price on Qiagen and gave the stock a “hold” rating in a research report on Friday, February 6th. Deutsche Bank Aktiengesellschaft lowered Qiagen from a “buy” rating to a “hold” rating and boosted their price target for the company from $52.00 to $54.00 in a research note on Thursday, January 22nd. JPMorgan Chase & Co. upped their price target on Qiagen from $55.00 to $60.00 and gave the company an “overweight” rating in a report on Friday, February 6th. Finally, Robert W. Baird set a $53.00 price objective on Qiagen in a research report on Friday, February 6th. Four research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $55.20.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.